Kaufmann H, Brannan T, Krakoff L, Yahr M D, Mandeli J
Department of Neurology, Mount Sinai Hospital, New York, NY 10029.
Neurology. 1988 Jun;38(6):951-6. doi: 10.1212/wnl.38.6.951.
The therapeutic efficacy of midodrine, an alpha-adrenergic agonist that does not cross the blood-brain barrier, was investigated in a double-blind crossover trial in seven patients with orthostatic hypotension due to autonomic failure. We identified two groups of patients: those in whom upright mean arterial pressure significantly increased (group I, n = 3) and those in whom upright mean arterial pressure decreased (group II, n = 4) during midodrine treatment. Body weight changed in a parallel manner with upright blood pressure, increasing in patients of group I and decreasing in patients of group II (p less than 0.05). Autonomic cardiovascular reflexes were significantly more impaired in patients of group II than in patients of group I. We conclude that midodrine is effective in the treatment of orthostatic hypotension only in those patients with significant preservation of autonomic reflexes. Conversely, in patients with markedly impaired baroreceptor mechanisms, treatment with midodrine may produce extracellular fluid volume depletion and exacerbate orthostatic hypotension.
米多君是一种不能透过血脑屏障的α-肾上腺素能激动剂,在一项双盲交叉试验中,研究人员对7名因自主神经功能衰竭导致体位性低血压的患者使用该药进行了治疗。我们将患者分为两组:在使用米多君治疗期间,直立平均动脉压显著升高的患者(第一组,n = 3)和直立平均动脉压降低的患者(第二组,n = 4)。体重变化与直立血压呈平行关系,第一组患者体重增加,第二组患者体重下降(p < 0.05)。第二组患者的自主心血管反射受损程度明显高于第一组患者。我们得出结论,米多君仅对那些自主反射功能显著保留的患者治疗体位性低血压有效。相反,在压力感受器机制明显受损的患者中,使用米多君治疗可能会导致细胞外液容量减少,并加重体位性低血压。